Enhancing Patients’ Access to Genomic Diagnostics

A Proposal for Reform of the French Healthcare System to Allow Broader Adoption of Genomic Testing

Genomic profiling, using Genomic Diagnostics, has been defined as “a laboratory method that is used to learn about the genes in a person or in a specific cell type, and the way those genes interact with each other and with the environment.”

Genomic Diagnostics can fundamentally transform healthcare for three main reasons: significantly increasing the breadth, depth and accuracy of the analysis of human health and disease for each patient profiled, bringing more accurate and actionable diagnostic information earlier in the course of disease, and significant economic and societal value through a growing global industry which will positively impact lives of patients around the globe.

To examine the issue of patients’ access to Genomic Diagnostics, Alira Health and EUCOPE have collaborated to create a position paper, addressed to all stakeholders in the French healthcare system: physicians, payers, providers (including hospitals and labs), procurement teams, policy makers, and, of course, patients and their advocates. Continue reading to get the overview of the recommendations that will enhance the Genomic Diagnostics ecosystem in France.

Blog
Published on:
February 15, 2023
If these systemic barriers can be overcome, the French Genomic Diagnostics ecosystem would be fundamentally reformed, improving health outcomes and lowering total healthcare system costs.
The Challenge Presented by Systemic Barriers

While France is a pioneer in ground-breaking genomic innovation, the country has systemic barriers that limit patient access to Genomic Diagnostics. These barriers include early funding programs becoming a bottleneck for innovation, inadequate reimbursement to enable a shift from research use to routine clinical practice, and a general lack of consideration for the patient perspective on Genomic Diagnostics and genomics.

Due to these barriers, access to genomic testing is limited, and the result is nothing less than sub-optimal outcomes for patients. The French healthcare system is also overlooking potential cost-savings due to inefficient care provision across the entire patient pathway. If these systemic barriers can be overcome, the French Genomic Diagnostics ecosystem would be fundamentally reformed, improving health outcomes and lowering total healthcare system costs.

Key Recommendations

To enable this shift, Alira Health and EUCOPE have conducted a robust research process, resulting in these three key recommendations to enhance the Genomic Diagnostics ecosystem in France:

  1. Modify existing early access pathways to enable faster and appropriate reimbursement of promising innovative Genomic Diagnostics, with a clear evidence-based evaluation pathway to determine long term reimbursement.
  2. Facilitate the integration of Genomic Diagnostics into clinical practice by establishing real-world evidence for diagnostics in the context of reimbursement.
  3. Increase the weighting of the patients’ perspective on the value of Genomic Diagnostics in the evaluation process for the reimbursement of Genomic Diagnostics

We encourage all stakeholders in the Genomic Diagnostics ecosystem in France to urgently review and implement the recommendations set forth in this position paper. Patient outcomes will improve, total costs will be minimized, and the French healthcare ecosystem will benefit from the integration and utilization of these tests.

Related news

Events April 10, 2024
European Patients as Partners in Clinical Research 2024
Join our panel at the European Patients as Partners event: "The Impact of Patient Involvement Along the Product Lifecycle."
Patient Centricity Patient Engagement
Case Studies March 26, 2024
Pharma Company Overcomes Launch Challenges with Patient-Centric Strategy
Our patient engagement team helped this pharma client identify the drivers behind the challenges they faced with their product launch.
Patient Centricity Patient Engagement Pharma
Blog March 13, 2024
Strategic Patient Engagement as a Game Changer for Your Product Success
This FAQ addresses popular questions about how to make patient engagement the core of a product development and commercialization strategy.
Patient Centricity Patient Engagement
Case Studies March 12, 2024
Pharma Company Adopts a Patient-Centric Value Proposition for Regulatory and Payer Dossier
A pharma company had a wealth of patient data on a product in development and they wanted to create a long-term strategy that would create a continuity of patient engagement across(...)
Patient Centricity Patient Engagement Pharma
Blog February 21, 2024
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Healthcare Technology Patient Engagement Rare Disease
Events January 17, 2024
Presentation: Pilot Project for the Inclusion of the Patient Voices in the Regional Market Access Drug Committees in Spain
On January 23rd we will present the results of the first phase of the “Pilot Project for the Inclusion of the Patient Voices in the Regional Market Access Drug Committees in Spain.”
Market Access Patient Engagement Spain
Blog January 12, 2024
On Our Way to
Patient-Enabled Solutions
The natural evolution of healthcare in many of its forms is patient-enabled healthcare. CEO Gabriele Brambilla weighs in.
Patient Advocacy Patient Centricity Patient Engagement
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.